Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels.
Rochlitz C, Dreno B, Jantscheff P, Cavalli F, Squiban P, Acres B, Baudin M, Escudier B, Heinzerling L, Morant R, Herrmann R, Dietrich PY, Dummer R. Rochlitz C, et al. Among authors: baudin m. Cancer Gene Ther. 2002 Mar;9(3):289-95. doi: 10.1038/sj.cgt.7700441. Cancer Gene Ther. 2002. PMID: 11896446 Clinical Trial.
Metastatic Breast Tumour Regression Following Treatment by a Gene-Modified Vaccinia Virus Expressing MUC1 and IL-2.
Scholl S, Squiban P, Bizouarne N, Baudin M, Acres B, Von Mensdorff-Pouilly S, Shearer M, Beuzeboc P, Van Belle S, Uzielly B, Pouillart P, Taylor-Papadimitriou J, Miles D. Scholl S, et al. Among authors: baudin m. J Biomed Biotechnol. 2003;2003(3):194-201. doi: 10.1155/S111072430320704X. J Biomed Biotechnol. 2003. PMID: 12975534 Free PMC article.
A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C.
Habersetzer F, Honnet G, Bain C, Maynard-Muet M, Leroy V, Zarski JP, Feray C, Baumert TF, Bronowicki JP, Doffoël M, Trépo C, Agathon D, Toh ML, Baudin M, Bonnefoy JY, Limacher JM, Inchauspé G. Habersetzer F, et al. Among authors: baudin m. Gastroenterology. 2011 Sep;141(3):890-899.e1-4. doi: 10.1053/j.gastro.2011.06.009. Epub 2011 Jun 13. Gastroenterology. 2011. PMID: 21699798 Clinical Trial.
Immunogenicity and safety of one dose of diphtheria, tetanus, acellular pertussis and poliomyelitis vaccine (Repevax®) followed by two doses of diphtheria, tetanus and poliomyelitis vaccine (Revaxis®) in adults aged ≥ 40 years not receiving a diphtheria- and tetanus-containing vaccination in the last 20 years.
Dominicus R, Galtier F, Richard P, Baudin M. Dominicus R, et al. Among authors: baudin m. Vaccine. 2014 Jun 30;32(31):3942-9. doi: 10.1016/j.vaccine.2014.05.034. Epub 2014 May 19. Vaccine. 2014. PMID: 24852717
Immunogenicity of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine compared to standard-dose diphtheria, tetanus, acellular pertussis when used as a pre-school booster in UK children: A 5-year follow-up of a randomised controlled study.
John T, Voysey M, Yu LM, McCarthy N, Baudin M, Richard P, Fiquet A, Kitchin N, Pollard AJ. John T, et al. Among authors: baudin m. Vaccine. 2015 Aug 26;33(36):4579-85. doi: 10.1016/j.vaccine.2015.06.105. Epub 2015 Jul 10. Vaccine. 2015. PMID: 26165918 Free article. Clinical Trial.
Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip) to adults aged ≥60 years: an open-label, randomised trial.
Zimmermann U, Gavazzi G, Richard P, Eymin C, Soubeyrand B, Baudin M. Zimmermann U, et al. Among authors: baudin m. Vaccine. 2013 Mar 1;31(11):1496-502. doi: 10.1016/j.vaccine.2012.12.081. Epub 2013 Jan 10. Vaccine. 2013. PMID: 23313654 Clinical Trial.
85 results